{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T20:24:19Z","timestamp":1791923059051,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011733","name":"Liga Portuguesa Contra o Cancro","doi-asserted-by":"publisher","award":["03\/22"],"award-info":[{"award-number":["03\/22"]}],"id":[{"id":"10.13039\/501100011733","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CUF","award":["BDM\/2021"],"award-info":[{"award-number":["BDM\/2021"]}]},{"name":"Portuguese Association of Urology","award":["BI-APU 2019"],"award-info":[{"award-number":["BI-APU 2019"]}]},{"DOI":"10.13039\/501100005727","name":"Universidade de Coimbra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005727","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Urothelial bladder cancer (BCa) is marked by high recurrence and mortality, and the efficacy of PD-1\/PD-L1 immunotherapy remains limited because of immune evasion. The adenosinergic pathway (AP), mediated by ectonucleotidases CD39 and CD73, is a key immunosuppressive mechanism, but its role in BCa remains unclear. We conducted an integrated immunophenotypic analysis of peripheral blood (PB) and the tumor microenvironment (TME) from 39 patients with BCa and 14 healthy controls using multicolor flow cytometry and immunohistochemistry. High-risk (HR) patients exhibited systemic immunosuppression, characterized by an elevated neutrophil-to-lymphocyte ratio and increased circulating regulatory T cells (Tregs), along with reduced cytotoxic \u03b3\u03b4 T cells and diminished Th1\/Tc1 functional subtypes. In the TME, we observed reduced CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell infiltration accompanied by increased Tregs, and phenotypes characterized by poor immune infiltration in the tumor core predominated across the cohort. In both PB and the TME, CD39 and CD73 expression on T cells strongly correlated with an immunosuppressive environment, marked by increased M2-like macrophages and decreased effector T cells. Circulating double-positive T cells (CD4\n                    <jats:sup>+<\/jats:sup>\n                    CD39\n                    <jats:sup>+<\/jats:sup>\n                    CD73\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    CD39\n                    <jats:sup>+<\/jats:sup>\n                    CD73\n                    <jats:sup>+<\/jats:sup>\n                    ) mirrored the intratumoral T-cell composition, suggesting their potential as non-invasive biomarkers. Elevated frequencies of circulating single-positive CD8\n                    <jats:sup>+<\/jats:sup>\n                    CD39\n                    <jats:sup>+<\/jats:sup>\n                    and CD8\n                    <jats:sup>+<\/jats:sup>\n                    CD73\n                    <jats:sup>+<\/jats:sup>\n                    T-cells were significantly associated with higher pathological grade and distinguished high-grade tumors with moderate accuracy (AUC\u2009&gt;\u20090.70). This study demonstrates that BCa is characterized by extensive AP-linked immunosuppression, and that specific ectonucleotidase-expressing circulating T-cell subsets may serve as non-invasive biomarkers for assessing tumor infiltration and grade.\n                  <\/jats:p>","DOI":"10.1007\/s00262-026-04400-4","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:53:28Z","timestamp":1776862408000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["CD39\/CD73-mediated immunosuppression and tumor aggressiveness in bladder cancer"],"prefix":"10.1007","volume":"75","author":[{"given":"Frederico","family":"Furriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Laranjeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarida","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Fontinha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edtor","family":"Sousa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9lia","family":"Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9911-4926","authenticated-orcid":false,"given":"Belmiro","family":"Parada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Paiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,22]]},"reference":[{"key":"4400_CR1","first-page":"557","volume":"20182020","author":"J Ferlay","year":"2024","unstructured":"Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Pi\u00f1eros M, Znaor A, Soerjomataram I, Bray F (2024) Global cancer observatory: cancer today. Int Agency Res Cancer 20182020:557\u2013567","journal-title":"Int Agency Res Cancer"},{"key":"4400_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41571-023-00744-3","volume":"20","author":"LMC Van Hoogstraten","year":"2023","unstructured":"Van Hoogstraten LMC, Vrieling A, Van Der Heijden AG, Kogevinas M, Richters A, Kiemeney LA (2023) Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice. Nat Rev Clin Oncol 20:287\u2013304. https:\/\/doi.org\/10.1038\/s41571-023-00744-3","journal-title":"Nat Rev Clin Oncol"},{"key":"4400_CR3","doi-asserted-by":"publisher","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"H von der Maase","year":"2005","unstructured":"von der Maase H, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, Moore MJ, Zimmermann A, Arning M (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602\u20134608. https:\/\/doi.org\/10.1200\/JCO.2005.07.757","journal-title":"J Clin Oncol"},{"key":"4400_CR4","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1002\/cncr.22031","volume":"107","author":"A Dash","year":"2006","unstructured":"Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G, Bochner BH (2006) Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107:506\u2013513. https:\/\/doi.org\/10.1002\/cncr.22031","journal-title":"Cancer"},{"key":"4400_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.18053\/jctres.07.202104.009","volume":"7","author":"Z Yang","year":"2021","unstructured":"Yang Z (2021) Immune escape mechanisms and immunotherapy of urothelial bladder cancer. J Clin Transl Res. 7:485. https:\/\/doi.org\/10.18053\/jctres.07.202104.009","journal-title":"J Clin Transl Res."},{"key":"4400_CR6","doi-asserted-by":"publisher","first-page":"1235884","DOI":"10.3389\/fimmu.2023.1235884","volume":"14","author":"J Van Dorp","year":"2023","unstructured":"Van Dorp J, Van Der Heijden MS (2023) The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. Front Immunol 14:1235884. https:\/\/doi.org\/10.3389\/fimmu.2023.1235884","journal-title":"Front Immunol"},{"key":"4400_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.ccell.2019.10.007","volume":"36","author":"D Boison","year":"2019","unstructured":"Boison D, Yegutkin GG (2019) Adenosine metabolism: emerging concepts for cancer therapy. Cancer Cell 36:582\u2013596. https:\/\/doi.org\/10.1016\/j.ccell.2019.10.007","journal-title":"Cancer Cell"},{"key":"4400_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/s41571-020-0382-2","volume":"17","author":"B Allard","year":"2020","unstructured":"Allard B, Allard D, Buisseret L, Stagg J (2020) The adenosine pathway in immuno-oncology. Nat Rev Clin Oncol 17:611\u2013629. https:\/\/doi.org\/10.1038\/s41571-020-0382-2","journal-title":"Nat Rev Clin Oncol"},{"key":"4400_CR9","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.jid.2018.10.016","volume":"139","author":"C Silva-Vilches","year":"2019","unstructured":"Silva-Vilches C, Ring S, Schrader J, Clausen BE, Probst H-C, Melchior F, Schild H, Enk A, Mahnke K (2019) Production of extracellular adenosine by CD73+ dendritic cells is crucial for induction of tolerance in contact hypersensitivity reactions. J Invest Dermatol 139:541\u2013551. https:\/\/doi.org\/10.1016\/j.jid.2018.10.016","journal-title":"J Invest Dermatol"},{"key":"4400_CR10","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00262-020-02535-6","volume":"69","author":"SS Jeske","year":"2020","unstructured":"Jeske SS, Brand M, Ziebart A, Laban S, Doescher J, Greve J, Jackson EK, Hoffmann TK, Brunner C, Schuler PJ (2020) Adenosine-producing regulatory B cells in head and neck cancer. Cancer Immunol Immunother 69:1205\u20131216. https:\/\/doi.org\/10.1007\/s00262-020-02535-6","journal-title":"Cancer Immunol Immunother"},{"key":"4400_CR11","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1016\/j.trecan.2019.10.007","volume":"5","author":"K Mehla","year":"2019","unstructured":"Mehla K, Singh PK (2019) Metabolic regulation of macrophage polarization in cancer. Trends Cancer 5:822\u2013834. https:\/\/doi.org\/10.1016\/j.trecan.2019.10.007","journal-title":"Trends Cancer"},{"key":"4400_CR12","doi-asserted-by":"publisher","first-page":"2149","DOI":"10.2147\/OTT.S297272","volume":"14","author":"W Zhu","year":"2021","unstructured":"Zhu W, Zhao Z, Feng B, Yu W, Li J, Guo H, Yang R (2021) CD8+CD39+ T Cells mediate anti-tumor cytotoxicity in bladder cancer. OncoTargets Ther 14:2149\u20132161. https:\/\/doi.org\/10.2147\/OTT.S297272","journal-title":"OncoTargets Ther"},{"key":"4400_CR13","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.18632\/oncotarget.28029","volume":"12","author":"JM Ferreira","year":"2021","unstructured":"Ferreira JM, Matheus LHG, Almeida RVSde, Melo PAdeS, Leite KRM, Murta CB, Claro JFdeA, Camacho CP, Pontes-J\u00fanior J, Dell\u00ea H (2021) High CD39 expression is associated with the non-muscle-invasive phenotype of human bladder cancer. Oncotarget 12:1580\u20131586. https:\/\/doi.org\/10.18632\/oncotarget.28029","journal-title":"Oncotarget"},{"key":"4400_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/785461","volume":"2015","author":"MS Wettstein","year":"2015","unstructured":"Wettstein MS, Buser L, Hermanns T, Roudnicky F, Eberli D, Baumeister P, Sulser T, Wild P, Poyet C (2015) CD73 predicts favorable prognosis in patients with nonmuscle-invasive urothelial bladder cancer. Dis Markers 2015:1\u20138. https:\/\/doi.org\/10.1155\/2015\/785461","journal-title":"Dis Markers"},{"key":"4400_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.coph.2020.07.001","volume":"53","author":"M Roh","year":"2020","unstructured":"Roh M, Wainwright DA, Wu JD, Wan Y, Zhang B (2020) Targeting CD73 to augment cancer immunotherapy. Curr Opin Pharmacol 53:66\u201376. https:\/\/doi.org\/10.1016\/j.coph.2020.07.001","journal-title":"Curr Opin Pharmacol"},{"key":"4400_CR16","doi-asserted-by":"publisher","first-page":"57327","DOI":"10.18632\/oncotarget.16905","volume":"8","author":"R Wang","year":"2017","unstructured":"Wang R, Zhang Y, Lin X, Gao Y, Zhu Y (2017) Prognositic value of CD73-adenosinergic pathway in solid tumor: a meta-analysis and systematic review. Oncotarget 8:57327\u201357336. https:\/\/doi.org\/10.18632\/oncotarget.16905","journal-title":"Oncotarget"},{"key":"4400_CR17","volume-title":"TNM classification of malignant tumors","author":"JD Brierley","year":"2016","unstructured":"Brierley JD et al (2016) TNM classification of malignant tumors, 8th edn. UICC International Union Against Cancer, Oxford","edition":"8"},{"key":"4400_CR18","unstructured":"Gontero P, Birtle A, Comp\u00e9rat E, Escrig JLD, Liedberg F, Mariappan P, Masson-Lecomte A, Shariat SF, Teoh J, Xylinas EN, Pradere B, Rai BP, Soria F, Soukup V (2025) EAU Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). In: EAU guidelines office. EAU Guidelines Office, Arnhem, The Netherlands"},{"key":"4400_CR19","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3390\/jpm12071073","volume":"12","author":"S Marletta","year":"2022","unstructured":"Marletta S, Fusco N, Munari E, Luchini C, Cimadamore A, Brunelli M, Querzoli G, Martini M, Vigliar E, Colombari R, Girolami I, Pagni F, Eccher A (2022) Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems. J Pers Med 12:1073. https:\/\/doi.org\/10.3390\/jpm12071073","journal-title":"J Pers Med"},{"key":"4400_CR20","doi-asserted-by":"publisher","first-page":"e36967","DOI":"10.7554\/eLife.36967","volume":"7","author":"JN Kather","year":"2018","unstructured":"Kather JN, Suarez-Carmona M, Charoentong P, Weis C-A, Hirsch D, Bankhead P, Horning M, Ferber D, Kel I, Herpel E, Schott S, Z\u00f6rnig I, Utikal J, Marx A, Gaiser T, Brenner H, Chang-Claude J, Hoffmeister M, J\u00e4ger D, Halama N (2018) Topography of cancer-associated immune cells in human solid tumors. Elife 7:e36967. https:\/\/doi.org\/10.7554\/eLife.36967","journal-title":"Elife"},{"key":"4400_CR21","doi-asserted-by":"publisher","first-page":"793964","DOI":"10.3389\/fimmu.2021.793964","volume":"12","author":"NV Dijk","year":"2021","unstructured":"Dijk NV, Gil-Jimenez A, Silina K, Montfoort MLV, Einerhand S, Jonkman L, Voskuilen CS, Peters D, Sanders J, Lubeck Y, Broeks A, Hooijberg E, Vis DJ, Broek MVD, Wessels LFA, Rhijn BWGV, Heijden MSVD (2021) The tumor immune landscape and architecture of tertiary lymphoid structures in urothelial cancer. Front Immunol 12:793964. https:\/\/doi.org\/10.3389\/fimmu.2021.793964","journal-title":"Front Immunol"},{"issue":"5","key":"4400_CR22","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","volume":"54","author":"AJ Ozga","year":"2021","unstructured":"Ozga AJ, Chow MT, Luster AD (2021) Chemokines and the immune response to cancer. Immunity 54(5):859\u2013874. https:\/\/doi.org\/10.1016\/j.immuni.2021.01.012","journal-title":"Immunity"},{"key":"4400_CR23","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.2217\/fon-2023-0871","volume":"20","author":"N Kaplinsky","year":"2024","unstructured":"Kaplinsky N, Williams K, Watkins D, Adams M, Stanbery L, Nemunaitis J (2024) Regulatory role of CD39 and CD73 in tumor immunity. Future Oncol 20:1367\u20131380. https:\/\/doi.org\/10.2217\/fon-2023-0871","journal-title":"Future Oncol"},{"key":"4400_CR24","doi-asserted-by":"publisher","first-page":"118188","DOI":"10.1016\/j.biopha.2025.118188","volume":"188","author":"F Furriel","year":"2025","unstructured":"Furriel F, Ferreira H, Sampaio-Ribeiro G, Pereira M, Eloy C, Neves B, Paiva A, Parada B, Gomes C (2025) Co-targeting the CD73-adenosinergic axis enhances the anti-tumor efficacy of anti-PD-L1 immunotherapy in bladder cancer. Biomed Pharmacother 188:118188. https:\/\/doi.org\/10.1016\/j.biopha.2025.118188","journal-title":"Biomed Pharmacother"},{"key":"4400_CR25","doi-asserted-by":"publisher","first-page":"67.e1","DOI":"10.1016\/j.urolonc.2014.06.010","volume":"33","author":"R Mano","year":"2015","unstructured":"Mano R, Baniel J, Shoshany O, Margel D, Bar-On T, Nativ O, Rubinstein J, Halachmi S (2015) Neutrophil-to-lymphocyte ratio predicts progression and recurrence of non\u2013muscle-invasive bladder cancer. Urol Oncol Semin Orig Investig 33:67.e1-67.e7. https:\/\/doi.org\/10.1016\/j.urolonc.2014.06.010","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"4400_CR26","doi-asserted-by":"publisher","first-page":"11450","DOI":"10.18632\/oncotarget.7199","volume":"7","author":"W J\u00f3\u017awicki","year":"2016","unstructured":"J\u00f3\u017awicki W, Bro\u017cyna AA, Siekiera J, Slominski AT (2016) Frequency of CD4+CD25+Foxp3+ cells in peripheral blood in relation to urinary bladder cancer malignancy indicators before and after surgical removal. Oncotarget 7:11450\u201311462. https:\/\/doi.org\/10.18632\/oncotarget.7199","journal-title":"Oncotarget"},{"key":"4400_CR27","doi-asserted-by":"publisher","first-page":"1325343","DOI":"10.3389\/fimmu.2023.1325343","volume":"14","author":"A Kotwal","year":"2024","unstructured":"Kotwal A, Gustafson MP, Bornschlegl S, Dietz AB, Delivanis D, Ryder M (2024) Circulating immunophenotypes are potentially prognostic in follicular cell-derived thyroid cancer. Front Immunol 14:1325343. https:\/\/doi.org\/10.3389\/fimmu.2023.1325343","journal-title":"Front Immunol"},{"key":"4400_CR28","doi-asserted-by":"publisher","first-page":"488.e1","DOI":"10.1016\/j.urolonc.2023.10.001","volume":"41","author":"H Kobayashi","year":"2023","unstructured":"Kobayashi H, Kondo T, Iizuka J, Yoshida K, Takagi T (2023) A retrospective cohort study of the impact of peripheral blood gamma- delta T cells to prognosis of nonmetastatic renal cell cancer after curative resection. Urol Oncol Semin Orig Investig 41:488.e1-488.e9. https:\/\/doi.org\/10.1016\/j.urolonc.2023.10.001","journal-title":"Urol Oncol Semin Orig Investig"},{"key":"4400_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/iju.70044","author":"Y Fukiage","year":"2025","unstructured":"Fukiage Y, Muramoto A, Terada N, Kobayashi M (2025) Peritumoral infiltration of regulatory T Cells reduces the therapeutic efficacy of Bacillus Calmette\u2013Gu\u00e9rin therapy for bladder carcinoma in situ. Int J Urol. https:\/\/doi.org\/10.1111\/iju.70044","journal-title":"Int J Urol"},{"issue":"1","key":"4400_CR30","doi-asserted-by":"publisher","first-page":"8810","DOI":"10.1038\/s41598-018-27125-6","volume":"8","author":"P Metzger","year":"2018","unstructured":"Metzger P, Kirchleitner SV, Koenig LM, H\u00f6rth C, Kobold S, Endres S, Schnurr M, Duewell P (2018) Dying cells expose a nuclear antigen cross-reacting with anti-PD-1 monoclonal antibodies. Sci Rep 8(1):8810. https:\/\/doi.org\/10.1038\/s41598-018-27125-6","journal-title":"Sci Rep"},{"key":"4400_CR31","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/cas.13887","volume":"110","author":"B Wang","year":"2019","unstructured":"Wang B, Pan W, Yang M, Yang W, He W, Chen X, Bi J, Jiang N, Huang J, Lin T (2019) Programmed death ligand-1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder. Cancer Sci 110:489\u2013498. https:\/\/doi.org\/10.1111\/cas.13887","journal-title":"Cancer Sci"},{"key":"4400_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/mt.2013.219","volume":"22","author":"C Devaud","year":"2014","unstructured":"Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, Yong CS, Pegram HJ, Stacker SA, Achen MG, Stewart TJ, Snyder LA, Teng MW, Smyth MJ, Darcy PK, Kershaw MH (2014) Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Mol Ther 22:18\u201327. https:\/\/doi.org\/10.1038\/mt.2013.219","journal-title":"Mol Ther"},{"key":"4400_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","volume":"16","author":"Y Togashi","year":"2019","unstructured":"Togashi Y, Shitara K, Nishikawa H (2019) Regulatory T cells in cancer immunosuppression \u2014 implications for anticancer therapy. Nat Rev Clin Oncol 16:356\u2013371. https:\/\/doi.org\/10.1038\/s41571-019-0175-7","journal-title":"Nat Rev Clin Oncol"},{"key":"4400_CR34","doi-asserted-by":"publisher","first-page":"63204","DOI":"10.18632\/oncotarget.11434","volume":"7","author":"W Xiu","year":"2016","unstructured":"Xiu W, Ma J, Lei T, Zhang M, Zhou S (2016) Immunosuppressive effect of bladder cancer on function of dendritic cells involving of Jak2\/STAT3 pathway. Oncotarget 7:63204\u201363214. https:\/\/doi.org\/10.18632\/oncotarget.11434","journal-title":"Oncotarget"},{"key":"4400_CR35","doi-asserted-by":"publisher","first-page":"101042831771157","DOI":"10.1177\/1010428317711571","volume":"39","author":"B Zhang","year":"2017","unstructured":"Zhang B, Cao M, He Y, Liu Y, Zhang G, Yang C, Du Y, Xu J, Hu J, Gao F (2017) Increased circulating M2-like monocytes in patients with breast cancer. Tumor Biol 39:101042831771157. https:\/\/doi.org\/10.1177\/1010428317711571","journal-title":"Tumor Biol"},{"key":"4400_CR36","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.3390\/cells11101639","volume":"11","author":"A-M Larsson","year":"2022","unstructured":"Larsson A-M, Nordstr\u00f6m O, Johansson A, Ryd\u00e9n L, Leandersson K, Bergenfelz C (2022) Peripheral blood mononuclear cell populations correlate with outcome in patients with metastatic breast cancer. Cells 11:1639. https:\/\/doi.org\/10.3390\/cells11101639","journal-title":"Cells"},{"key":"4400_CR37","doi-asserted-by":"publisher","first-page":"e20240957","DOI":"10.1084\/jem.20240957","volume":"222","author":"A Ray","year":"2025","unstructured":"Ray A, Hu KH, Kersten K, Courau T, Kuhn NF, Zaleta-Linares I, Samad B, Combes AJ, Krummel MF (2025) Targeting CD206+ macrophages disrupts the establishment of a key antitumor immune axis. J Exp Med 222:e20240957. https:\/\/doi.org\/10.1084\/jem.20240957","journal-title":"J Exp Med"},{"key":"4400_CR38","doi-asserted-by":"publisher","first-page":"6740","DOI":"10.1038\/s41467-022-34495-z","volume":"13","author":"L Liu","year":"2022","unstructured":"Liu L, Hou Y, Deng C, Tao Z, Chen Z, Hu J, Chen K (2022) Single cell sequencing reveals that CD39 inhibition mediates changes to the tumor microenvironment. Nat Commun 13:6740. https:\/\/doi.org\/10.1038\/s41467-022-34495-z","journal-title":"Nat Commun"},{"key":"4400_CR39","doi-asserted-by":"publisher","first-page":"276","DOI":"10.22034\/iji.2023.97037.2527","volume":"20","author":"K Zhao","year":"2023","unstructured":"Zhao K, Han D, Tang L, Jin H (2023) CD39 expression in peripheral T cells is associated with clinicopathological characteristics in patients with cervical cancer. Iran J Immunol 20:276. https:\/\/doi.org\/10.22034\/iji.2023.97037.2527","journal-title":"Iran J Immunol"},{"key":"4400_CR40","doi-asserted-by":"publisher","first-page":"e004880","DOI":"10.1136\/jitc-2022-004880","volume":"10","author":"S Nguyen","year":"2022","unstructured":"Nguyen S, Chevalier MF, Benmerzoug S, Cesson V, Schneider AK, Rodrigues-Dias S-C, Dartiguenave F, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derr\u00e9 L (2022) V\u03b42 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments. J Immunother Cancer 10:e004880. https:\/\/doi.org\/10.1136\/jitc-2022-004880","journal-title":"J Immunother Cancer"},{"key":"4400_CR41","doi-asserted-by":"publisher","first-page":"1026954","DOI":"10.3389\/fimmu.2022.1026954","volume":"13","author":"C Kerneur","year":"2022","unstructured":"Kerneur C, Cano CE, Olive D (2022) Major pathways involved in macrophage polarization in cancer. Front Immunol 13:1026954. https:\/\/doi.org\/10.3389\/fimmu.2022.1026954","journal-title":"Front Immunol"},{"key":"4400_CR42","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1093\/carcin\/bgy154","volume":"40","author":"MK Koivisto","year":"2019","unstructured":"Koivisto MK, Tervahartiala M, Kenessey I, Jalkanen S, Bostr\u00f6m PJ, Salmi M (2019) Cell-type-specific CD73 expression is an independent prognostic factor in bladder cancer. Carcinogenesis 40:84\u201392. https:\/\/doi.org\/10.1093\/carcin\/bgy154","journal-title":"Carcinogenesis"},{"key":"4400_CR43","doi-asserted-by":"publisher","first-page":"672158","DOI":"10.3389\/fimmu.2021.672158","volume":"12","author":"X Chen","year":"2021","unstructured":"Chen X, Chen H, He D, Cheng Y, Zhu Y, Xiao M, Lan H, Wang Z, Cao K (2021) Analysis of tumor microenvironment characteristics in bladder cancer: implications for immune checkpoint inhibitor therapy. Front Immunol 12:672158. https:\/\/doi.org\/10.3389\/fimmu.2021.672158","journal-title":"Front Immunol"},{"key":"4400_CR44","doi-asserted-by":"publisher","first-page":"1744946","DOI":"10.1080\/2162402X.2020.1744946","volume":"9","author":"I Shevchenko","year":"2020","unstructured":"Shevchenko I, Mathes A, Groth C, Karakhanova S, M\u00fcller V, Utikal J, Werner J, Bazhin AV, Umansky V (2020) Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses. OncoImmunology 9:1744946. https:\/\/doi.org\/10.1080\/2162402X.2020.1744946","journal-title":"OncoImmunology"},{"key":"4400_CR45","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.21037\/atm-21-2589","volume":"9","author":"W Zheng","year":"2021","unstructured":"Zheng W, Zhu Y, Chen X, Zhao J (2021) CD73 expression in myeloid-derived suppressor cells is correlated with clinical stages in head and neck squamous cell carcinomas. Ann Transl Med 9:1148\u20131148. https:\/\/doi.org\/10.21037\/atm-21-2589","journal-title":"Ann Transl Med"},{"key":"4400_CR46","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3390\/cancers16040803","volume":"16","author":"F Alberca-del Arco","year":"2024","unstructured":"Alberca-del Arco F, Prieto-Cuadra D, Santos-Perez De La Blanca R, S\u00e1ez-Barranquero F, Matas-Rico E, Herrera-Imbroda B (2024) New perspectives on the role of liquid biopsy in bladder cancer: applicability to precision medicine. Cancers Basel 16:803. https:\/\/doi.org\/10.3390\/cancers16040803","journal-title":"Cancers Basel"},{"key":"4400_CR47","doi-asserted-by":"publisher","first-page":"e004089","DOI":"10.1136\/jitc-2021-004089","volume":"10","author":"RC Augustin","year":"2022","unstructured":"Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ (2022) Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer 10:e004089. https:\/\/doi.org\/10.1136\/jitc-2021-004089","journal-title":"J Immunother Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04400-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04400-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T12:53:30Z","timestamp":1776862410000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04400-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,22]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4400"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04400-4","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,22]]},"assertion":[{"value":"13 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"154"}}